נכסים נקיים למניה בודדת: bionomics.com.au (NEUP)
Neuphoria Therapeutics Inc. (NEUP) possesses an innovative pipeline for creating ion channel modulators to combat PTSD, which opens broad prospects. This chart of the stock's historical book value demonstrates net asset dynamics, with 4.51 representing the latest level. The company's revenues will be based on the therapy of cognitive impairments; however, geopolitical tensions and sanctions seriously hinder global trials and component logistics.
פילוחי נתונים אנליטיים מרוכזים עבור Neuphoria Therapeutics, Inc. (NEUP)
Book value per share determines the net asset value of a company minus all liabilities, serving as a fundamental anchor of capital reliability for the investor. By analyzing book value data on GURU.Markets, one can assess the financial stability of Neuphoria Therapeutics Inc. (NEUP), whose value in the defensive neuropsychiatry sector depends on clinical trial results rather than market conditions.